- 會員指數:
- 企業認證:
- 聯系人:李小姐(女士)
- 地區:北京
-
脫氧吡啶酚DPD ELISA試劑盒說明書
 |
|
|
 |
詳細介紹
脫氧吡啶啉DPD ELISA試劑盒 美國Metre INTENDED USE
MicroVue DPD is a urinary assay that provides a quantitative measure of the excretion of
deoxypyridinoline (DPD) crosslinks as an indicator of bone resorption. Elevated levels of urinary DPD indicate elevated bone resorption in individuals. Measurement of DPD is intended for use as an aid in monitoring bone resorption changes in postmenopausal women receiving hormonal or bisphosphonate antiresorptive therapies and in individuals diagnosed with osteoporosis.
脫氧吡啶啉DPD ELISA試劑盒 美國Metre SUMMARY AND EXPLANATION
Approximately 90% of the organic matrix of bone is type I collagen, a triple helical protein.1 Type I collagen of bone is crosslinked by specific molecules which provide rigidity and strength. Crosslinks of mature type I collagen in bone are the pyridinium crosslinks, pyridinoline (PYD) and
deoxypyridinoline (DPD).1,2 DPD is formed by the enzymatic action of lysyl oxidase on the amino acid lysine.3 DPD is released into the circulation during the bone resorption process.2-5 DPD is excreted unmetabolized in urine and is unaffected by diet,6 making it suitable for assessing resorption. Bone is constantly undergoing a metabolic process called remodeling.2,7 This includes a degradation process, bone resorption, mediated by the action of osteoclasts, and a building process, bone formation, mediated by the action of osteoblasts.2,7 Remodeling is required for the maintenance and overall health of bone and is tightly coupled; that is, resorption and formation are in balance.7 In abnormal states of bone metabolism this process becomes uncoupled and, when resorption exceeds formation, this results in a net loss of bone.7 The measurement
of specific degradation products of bone matrix provide analytical data of the rate of bone metabolism.2,4,5 Osteoporosis is a metabolic bone disease characterized by abnormal bone remodeling. It is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in susceptibility to fractures.8 The most common type of osteoporosis occurs in postmenopausal women as
a result of the estrogen deficiency produced by the cessation of ovarian function.7 Restoration of premenopausal estrogen levels by replacement therapy prevents bone loss and osteoporosis.7-10 Estrogens and a class of compounds known as bisphosphonates are antiresorptive
therapies which can be used to prevent bone loss or treat osteoporosis.7-12 Osteoporosis can also result from attaining an inadequate peak bone mass during the growing years, an age-related imbalance of bone remodeling with a net excess of resorption, and a number of clinical conditions and therapies which induce bone loss or bone remodeling imbalances.7 These include endocrine diseases such as hypo-gonadism, hyperthyroidism, hyperparathyroidism, and hypercortisolism;
gastrointestinal diseases related to nutrition and mineral metabolism; connective tissue diseases; multiple myeloma; chronic immobilization, alcoholism, or tobacco use; and chronic therapy with heparin or corticosteroids.7 Other diseases characterized by abnormal bone remodeling include Paget’s disease and cancers metastatic to bone.3 For the MicroVue DPD assay, antibody technology was employed to produce a monoclonal antibody that demonstrates specificity for DPD.13 The specificity of the monoclonal antibody used in the MicroVue DPD assay allows for simple, convenient, reproducible and direct quantitation of DPD in urine.
關鍵詞：脫氧吡啶啉DPD ELISA試劑盒，吡啶啉（ PYD ）ELISA試劑盒，破骨細胞檢測，骨吸收，骨形成，骨質疏松癥，雙磷酸鹽化合物，雌激素水平，甲狀旁腺功能亢進癥，甲狀腺功能亢進，單克隆抗體
http://www.craymeibio.com/
推薦資料
本類下載排行
總下載排行